Associations of DMARDs with post-acute sequelae of COVID-19 in patients with systemic autoimmune rheumatic diseases: a prospective study
Authors' conclusion
CD20i users had significantly higher odds of PASC and fewer symptom-free days over the 28 days following COVID-19 diagnosis compared with csDMARD users.
Study context
- Population
- Patients with systemic autoimmune rheumatic diseases (SARDs) and confirmed COVID-19 infection at Mass General Brigham, 11 March 2021 to 17 June 2023analysed
- Participants
- 510 patients
- Exposure
- DMARD classes at COVID-19 onset, vs csDMARD users
- Outcome
- PASC: any COVID-19 symptom that persisted for ≥28 days
Methodological detailslogistic regression, restricted mean survival time
- Logistic regression
- Restricted mean survival time
Main finding
As reported in the abstract
PASC
Each group vs csDMARDAdjusted odds ratio (95% CI)
CD20i
2.69(1.23–5.88)
IL-12/23i, IL-17Ai, IL-23i
3.03(1.08–8.49)
- Developed PASC (all patients)
- 202 (40%)
Observational data: associations, not effects.
Further findings
| Outcome | aOR (95% CI) |
|---|---|
| Symptom-free days in the 28 days after infectionCD20i vs csDMARD | −4.12 (−7.29 to −0.94) |
- Symptom-free days in the 28 days after infection: restricted mean survival time; CD20 inhibitor (CD20i) had fewer symptom-free days
Original publication
Associations of DMARDs with post-acute sequelae of COVID-19 in patients with systemic autoimmune rheumatic diseases: a prospective study. Rheumatology (Oxford). Published 9 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →